Return on investment of SGLT2 inhibitors and GLP-1 receptor agonists: Implications of real-world use for managed care

More on GLP-1 receptor agonists

• SGLT2 inhibitors link to lower dementia risk than GLP-1 drugs

  Diabetes & Vascular Disease Research · 4 Oct 2026

• GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk

  Diabetes, Obesity & Metabolism · 4 Oct 2026

• SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes

  Clinical Journal of the American Society of Nephrology · 4 Oct 2026

• GLP-1 agonists linked to lower dementia risk after COVID-19

  Drug Design, Development and Therapy · 5 Oct 2026